Berenberg Bank Reiterates Buy Rating for AstraZeneca (LON:AZN)

Berenberg Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report released on Monday,Digital Look reports. The brokerage currently has a GBX 140 ($1.74) price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on AZN. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a £140 ($174.19) target price on shares of AstraZeneca in a research report on Friday, November 22nd. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($98.74).

AstraZeneca Stock Performance

Shares of LON AZN traded down GBX 10 ($0.12) during midday trading on Monday, reaching £111.70 ($138.98). The company’s stock had a trading volume of 6,044,899 shares, compared to its average volume of 46,410,563. The stock has a market capitalization of £173.13 billion, a P/E ratio of 3,546.03, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a 50 day moving average price of £105.88 and a 200-day moving average price of £115.38. AstraZeneca has a 12-month low of GBX 9,461 ($117.72) and a 12-month high of £133.88 ($166.58).

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Pascal Soriot purchased 20,000 shares of the stock in a transaction on Thursday, November 14th. The shares were purchased at an average price of £102.03 ($126.95) per share, with a total value of £2,040,600 ($2,539,007.09). Also, insider Tony Mok purchased 1,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average price of £126.80 ($157.77) per share, with a total value of £190,200 ($236,655.47). Corporate insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.